SCHEDULE: Morgan Stanley Reports Stake in Agios Pharmaceuticals

Morgan Stanley has updated its beneficial ownership filing for Agios Pharmaceuticals, Inc., reporting a 5.7% stake as of September 30, 2026.

Summary

• Morgan Stanley has filed a Schedule 13G, indicating a change in its beneficial ownership of Agios Pharmaceuticals, Inc. common stock.
• As of September 30, 2026, Morgan Stanley beneficially owns 3,431,830 shares, representing 5.7% of the class of securities.
• This filing is made under Rule 13d-1(b) and Morgan Stanley is identified as a broker or dealer registered under section 15 of the Act.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new financial or strategic information.

Positives

• Morgan Stanley's updated filing provides transparency regarding its investment in Agios Pharmaceuticals.
• The filing confirms that the investment is in the ordinary course of business, suggesting a standard investment activity.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Agios Pharmaceuticals.
• The information is limited to beneficial ownership and does not offer insights into the company's operational health.

Risks

• As a Schedule 13G filing, it primarily reports ownership and does not detail specific risks related to Agios Pharmaceuticals' business operations or market conditions.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Agios Pharmaceuticals' future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release."

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Morgan Stanley is a routine disclosure for institutional investors crossing certain ownership thresholds. It provides transparency on significant holdings but does not offer new insights into Agios Pharmaceuticals' specific business operations or competitive positioning within the biopharmaceutical industry.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional investor's stake in the company.
• Management: Provides insight into the ownership structure and potential influence of major shareholders.

Next Steps

• Morgan Stanley will continue to monitor its beneficial ownership of Agios Pharmaceuticals, Inc. and file amendments to this Schedule 13G as required by SEC regulations.

Key Dates

Keywords

Agios Pharmaceuticals, Morgan Stanley, Schedule 13G, Beneficial Ownership, Investment, Common Stock, Securities